Elotuzumab in combination with pomalidomide and dexamethasone (EloPd) in relapsed refractory multiple myeloma (RRMM): a network meta-analysis

被引：0
|
作者：
Farrell, James [1 ]
Bertin, Nicolas [2 ]
Fischer, Claire [3 ]
Gauthier, Aline [4 ]
机构：
[1] Bristol Myers Squibb, Dublin, Ireland
[2] Amaris, Hlth Econ & Market Access, Paris, France
[3] Amaris, Hlth Econ & Market Access, Montreal, PQ, Canada
[4] Amaris, Hlth Econ & Market Access, Barcelona, Spain
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-244
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab in Combination with Pomalidomide and Dexamethasone (PEMBRO/POM/DEX) for Pomalidomide Exposed Relapsed or Refractory Multiple Myeloma
    Wilson, Lilly
    Cohen, Adam D.
    Weiss, Brendan M.
    Vogl, Dan T.
    Garfall, Alfred L.
    Capozzi, Donna L.
    Mangan, Patricia
    Sanchez, Mary
    Erb, Colleen
    Stadtmauer, Edward
    BLOOD, 2016, 128 (22)
  • [22] Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19): : 1811 - 1822
  • [23] Phase 3 Study of Pomalidomide with Cyclophosphamide and Dexamethasone Versus Pomalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN)
    Chng, Wee-Joo
    Li, Xinhua
    Lin, Cindy
    Kim, Jin Seok
    Handa, Hiroshi
    Durie, Brian G. M.
    BLOOD, 2020, 136
  • [24] Bendamustine in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: A phase II trial
    Kumar, Sudhir
    Sharma, Atul
    Malik, Prabhat Singh
    Gogia, Ajay
    Pathak, Neha
    Sahoo, Ranjit Kumar
    Gupta, Ritu
    Prasad, Chandra Prakash
    Kumar, Lalit
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 198 (02) : 288 - 297
  • [25] A Phase II Study of Venetoclax in Combination With Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
    Gasparetto, Cristina
    Bowles, Kristian M.
    Abdallah, Al-Ola
    Morris, Lura
    Mander, Gudrun
    Coppola, Sheryl
    Wang, Jing
    Ross, Jeremy A.
    Bueno, Orlando F.
    Arriola, Emma
    Mateos, Maria Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (11): : 775 - 784
  • [26] Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM)
    Dhakal, Binod
    Mohan, Meera
    Narra, Ravi
    Palen, Katie
    Szabo, Aniko
    Kearl, Tyce
    Ravi, Gayathri
    Bal, Susan
    Johnson, Bryon D.
    Pasquini, Marcelo
    D'Souza, Anita
    Hari, Parameswaran N.
    Costa, Luciano
    BLOOD, 2023, 142
  • [27] A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
    Yashar, David
    Spektor, Tanya M.
    Martinez, Daisy
    Ghermezi, Matthew
    Swift, Regina A.
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    Berenson, James R.
    LEUKEMIA & LYMPHOMA, 2022, 63 (04) : 975 - 983
  • [28] A Phase 2 Trial of the Efficacy and Safety of Elotuzumab in Combination with Pomalidomide, Carfilzomib and Dexamethasone for High Risk Relapsed/Refractory Multiple Myeloma Patients
    Berenson, James
    Martinez, Daisy
    Spektor, Tanya
    Sanchez, Armando
    Ghermezi, Matthew
    Swift, Regina
    Eades, Benjamin
    Schwartz, Gary
    Eshaghian, Shahrooz
    Lim, Stephen
    Vescio, Robert
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E249 - E250
  • [29] ELOQUENT-3 Trial: Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma Final Overall Survival Analysis
    Raab, Marc-Steffen
    Dimopoulos, Meletios
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    Leblanc, Richard
    Suzuki, Kenshi
    Richardson, Paul G.
    Mckiver, Mihaela Popa
    Jou, Ying-Ming
    Yao, David
    Das, Prianka
    San-Miguel, Jesus
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 174 - 174
  • [30] Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma
    Ide, Takafumi
    Osawa, Mayu
    Sanghavi, Kinjal
    Vezina, Heather E.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 129 - 140
12345